Spero Therapeutics Inc
SPRO
NASDAQ. Currency in USD
1.61 -0.07 ( -4.17% )
Market Cap.
83.36M
Beta (5Y monthly)
0.76
Price/Earnings
-
EPS (TTM)
-3.11
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
745,182
1y Target Est.
6.33
Day's Range
52 Week's Range
Historical Summary
Performance
1 Month
-13.90%
YTD
-89.94%
1Y
-88.15%
2Y
-90.90%
-69.87% ann.
3Y
-85.36%
-47.29% ann.
5Y
-84.95%
-31.54% ann.
10Y
7.44%
0.72% ann.
EPS growth
1Y
-16.48%
2Y
26.82%
12.63% ann.
3Y
-20.54%
7.38% ann.
Share Buybacks
3 Months
-8.81%
6 Months
-10.05%
1Y
-11.67%
2Y
-63.59%
3Y
-92.30%
5Y
-167.82%
About Spero Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Website
https://sperotherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
32.32M
Employees
41
Address
675 Massachusetts Avenue, Cambridge, MA, United States, 02139
Latest news
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a...
By GlobeNewswire Inc. - 10 weeks ago

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for...
By Zacks Investment Research - 11 weeks ago
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which...
By GlobeNewswire Inc. - 11 weeks ago

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the...
By Zacks Investment Research - 12 weeks ago

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter...
By Zacks Investment Research - 12 weeks ago

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for...
By Zacks Investment Research - 12 weeks ago
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a...
By GlobeNewswire Inc. - 12 weeks ago
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset...
By GlobeNewswire Inc. - 12 weeks ago